Peringkat dalam Saham
#24690
ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company focused on... ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company focused on creating innovative therapies derived from red blood cells. These treatments target various types of cancer and rare (orphan) diseases, with the company operating in both France and the United States. Its primary experimental drug, eryaspase, is currently undergoing Phase 3 clinical trials for patients battling second-line pancreatic cancer. Furthermore, this candidate is also in Phase 2 development for triple-negative breast cancer and for individuals with second-line acute lymphoblastic leukemia. The company is additionally advancing erymethionase, a preclinical-stage product. This candidate utilizes methionine-gamma-lyase, encased within red blood cells, to specifically address cancers that are dependent on methionine for growth. Established in 2004, ERYTECH Pharma's corporate headquarters are situated in Lyon, France.
Harga Saham
$0.95011029
Terakhir disinkronkan: 2023-06-28
Kapitalisasi Pasar
$57.72M
Perubahan (1 tahun)
0.00%
Perdagangan ERYTECH Pharma S.A. (ERYP)
Harga ERYP dengan kapitalisasi pasar B
Kapitalisasi pasar dari ERYTECH Pharma S.A.(ERYP)
Kapitalisasi Pasar: $57.72M
Per August 2026, ERYTECH Pharma S.A. memiliki kapitalisasi pasar sebesar $57.72M. Ini menjadikan ERYTECH Pharma S.A. sebagai perusahaan 24690th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar ERYTECH Pharma S.A. dari 2013 hingga 2026
ERYP dibandingkan dengan 5 teratas stocks paling populer
| Harga ERYP |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.257T
|
+9,107,659.38%
|
|
|
|
|
$4.599T
|
+7,967,295.80%
|
|
|
|
|
$4.107T
|
+7,114,761.75%
|
|
|
|
|
$3.577T
|
+6,197,671.28%
|
|
|
|
|
$2.807T
|
+4,863,697.60%
|
